Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
Business Wire•30/10/2026•00:15 ET
3
Key Highlights
- ➤Revenue 1.167 trillion yen, up 19.7% year-over-year, driven by Enhertu and Datroway
- ➤Operating profit 193.8 billion yen, up 34.4% year-over-year
- ➤Enhertu revenue 500.0 billion yen, up 51.4% year-over-year including milestones
- ➤Datroway revenue 54.4 billion yen, up 161.6% year-over-year including milestones
- ➤Fiscal 2026 guidance unchanged at 2.34 trillion yen revenue and 320.0 billion yen operating profit
Expert Statements
Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo
“Strong revenue growth continues in the second quarter of fiscal year 2026, driven by Enhertu and Datroway. These medicines have received nine new approvals across multiple indications since last quarter, including same day breast cancer approvals in Japan and China, which will allow us to bring these medicines to more patients”
Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo
“We also continue to explore novel combination strategies to deliver greater benefits to more patients through our DXd antibody drug conjugates as demonstrated by our new clinical trial collaboration to evaluate Datroway with ivonescimab.”
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
* Revenue increased 19.7% to 1.167 trillion yen year-over-year driven by Enhertu(®) and Datroway(®)
Get started
Create a free account to read the full story.